# NCT03539744 (NCT03539744)

> A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03539744
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AbbVie
- Conditions: Multiple Myeloma
- Interventions: Pomalidomide; Dexamethasone; Venetoclax
- Enrollment: 265
- Primary outcome: Progression-Free Survival (PFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03539744